Close Video Player

``We're engaging physicians and patients with the possibilities of the genetic world.``

Anne Wojcicki CEO | 23andMe

Improving consumer health is in our DNA.

23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome.

23andMe offers two saliva-based, over-the-counter genotyping services: Health + Ancestry Service or an Ancestry + Traits Service option. Over 150 genetic reports are returned directly to customers through a private and secure account online. The analysis includes information on Health Predisposition (including Genetic Health Risk), Pharmacogenetics, Carrier Status*, Ancestry, Wellness, and Traits that enables consumers to learn about genetics and to engage in conversations about their health and family history with their healthcare provider. In certain cases, additional features to the Health + Ancestry service are available.

The first and only direct-to-consumer DNA test that includes FDA-authorized Genetic Health Risk, Cancer Predisposition, Carrier Status, and Pharmacogenetics reports. As new reports receive market authorization from the FDA and as genomics knowledge continues to advance, eligible customers will receive additional genetic reports.

Accelerating research.
Making an impact.

Our innovative research platform has changed the research paradigm by enabling active consumer participation. 23andMe has millions of customers worldwide, with ~80% of customers consenting to participate in research. It is currently the world’s largest consented, re-contactable database for genetic research. Our research has shed light on a host of new genetic variations associated with certain diseases while fostering a better understanding of consumer comprehension of direct-to-consumer genetic test results.

Research is conducted independently, in collaboration with third parties, including academic institutions such as the University of Chicago, the MRC Epidemiology Unit, the University of Cambridge, Stanford University and the Broad Institute of MIT and Harvard, companies such as Pfizer and Genentech, and nonprofits such as the Lupus Research Institute, The Michael J. Fox Foundation and the National Parkinson Foundation.

See our list of 150+ publications here.

Developing breakthrough medicines.

The 23andMe Therapeutics division was created in April 2015. The Therapeutics team is committed to discovering and developing novel therapies that can offer benefits for patients. This dedicated research and drug development group identifies novel targets using the 23andMe genetic database, generates lead compounds to these targets and performs preclinical research to support future clinical development. The team currently has research programs across several therapeutic areas, including skin, liver and cardiovascular diseases, oncology and immunological disorders (including asthma).

Personal, private & secure.

At 23andMe, our customers are in control of their genetic information. At their discretion, they can authorize 23andMe to share their data with family members, healthcare professionals or other institutions conducting disease research. We make every effort to ensure they have complete control over access to their information.

We will not share your patients’ individual data without their explicit consent, and we do not provide information to law enforcement unless we are required to comply with a valid subpoena or court order.

We also encourage your patients to understand the extent of their legal protection under the federal Genetic Information Nondiscrimination Act (GINA), which protects against employer and health insurance company discrimination based on one’s genetics.

23andMe customer data is protected by state-of-the-art physical, technical and administrative security measures.

Learn more about privacy.

Watch our webinar


Questions? Contact us at

*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and the 23andMe Type 2 Diabetes health predisposition report which is based on 23andMe research and has not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. For important information and limitations regarding each genetic health risk and carrier status report, visit

The 23andMe PGS test uses qualitative genotyping to detect 6 variants in 3 genes in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Results should be confirmed in a clinical setting with independent genetic testing before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For a complete list of the 6 variants tested, visit